Issue Preview
Q4 2025
Welcome to the Q4 2025 edition of APAC Insider magazine, your go-to quarterly source of all the most recent information and updates across the corporate landscape in the Asia Pacific…
Continue
Reading
Q3 2025
Welcome to the Q3 issue of our APAC Insider Magazine, your quarterly source for all of the latest news and updates from across the Asia Pacific region. Showcasing award-winning creative…
Continue
Reading
Q2 2025
Welcome to the Q2 issue of our APAC Insider magazine, your quarterly source for all of the latest news and updates from across the Asia Pacific region. Here we present…
Continue
Reading
Q1 2025
Welcome to the Q1 edition of APAC Insider magazine, your quarterly source for all of the latest news and updates from across the Asia Pacific region. Covering a range of…
Continue
Reading
Q4 2024
Greetings from us at APAC Insider! Welcome to the Q4 edition of APAC Insider magazine, your go-to quarterly source for all the most recent information and updates across the corporate…
Continue
Reading
Q3 2024
Welcome to the Q3 edition of APAC Insider magazine, your quarterly source for all of the latest news and updates from across the Asia Pacific region. The APAC business landscape…
Continue
Reading
BACK TO TOP
About
Celosia Therapeutics Pty Ltd
Dr Kathryn Sunn is the CEO of Celosia Therapeutics, an Australian biotech developing first-in-class genetic therapies and diagnostic biomarkers for neurodegenerative diseases, including MND, FTD, and AD.
Under her leadership, Celosia raised $16.75 million in one of Australia’s largest Series A rounds for a preclinical biotech and, within 12 months, completed all milestones required to advance its lead gene therapy, CTx1000, to the Phase 1b clinical trial.
Visit Website
